Skip to content

Study · Non-randomized trial · n = 8 · 1979

5 results

Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man.

Huwyler R, Born W, Ohnhaus EE, Fischer JA

The American journal of physiology1 Jan 1979Cited by 30 (Europe PMC)

PMID571211 (opens in a new tab)DOI10.1152/ajpendo.1979.236.1.e15 (opens in a new tab)PepBankPUB-00571211
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In normal subjects, mainly intact salmon calcitonin was detected in plasma during infusion.

    In plain wordsIn normal subjects, mainly intact salmon calcitonin was detected in blood during infusion.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableIntact circulating peptide
    Study

    n = 8

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · constant infusion · 240 minAs given in this study (human).

    Source sentences

    Summary
    On gel filtration of plasma obtained during the infusions mainly intact hCT-(1--32) and sCT-(1--32) were recognized with homologous radioimmunoassay systems.
    1 context sentence
    Summary · context
    The metabolism and the urinary excretion of synthetic human and salmon calcitonin-(1--32) [hCT-(1--32), sCT-(1--32)] administered by constant infusions for 240 min were investigated in eight normal subjects.
  2. 02HumanNon-randomized trialPharmacokinetics

    In normal subjects, salmon calcitonin had lower metabolic clearance than human calcitonin at equal infusion doses.

    In plain wordsIn normal subjects, salmon calcitonin left the bloodstream more slowly than human calcitonin at equal doses.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseMetabolic clearance rate
    Study

    n = 8

    Comparator
    Human calcitonin at 0.04 mg
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.04 mg · constant infusion · 240 minAs given in this study (human).

    Measurements

    Metabolic clearance rate
    3.1 ml/kg per min
    salmon calcitonin
    Metabolic clearance rate
    8.4 ml/kg per min
    human calcitonin

    Source sentences

    Summary
    During constant infusions to equilibrium of 0.04 mg hCT-(1--32) and sCT-(1--32), the metabolic clearance rates (MCR) amounted to 8.4 +/- 1.1 and 3.1 +/- 0.1 ml/kg per min, respectively (P less than 0.01).
    1 context sentence
    Summary · context
    The metabolism and the urinary excretion of synthetic human and salmon calcitonin-(1--32) [hCT-(1--32), sCT-(1--32)] administered by constant infusions for 240 min were investigated in eight normal subjects.
  3. 03HumanNon-randomized trialPharmacokinetics

    In normal subjects, metabolic clearance with salmon calcitonin 0.04 mg was lower than with human calcitonin infused at 1 or 4 mg/240 min.

    In plain wordsIn normal subjects, salmon calcitonin at 0.04 mg was cleared more slowly than human calcitonin given at 1 or 4 mg/240 min.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseClearance versus human calcitonin at 1 and 4 mg/240 min
    Study

    n = 8

    Comparator
    Human calcitonin at 1 and 4 mg/240 min
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.04 mg · constant infusion · 240 minAs given in this study (human).

    Source sentences

    Summary
    When hCT-(1--32) was infused at rates of 1 and 4 mg/240 min, the MCR were lower than with 0.04 mg hCT-(1--32), but still higher than with 0.04 mg sCT-(1--32).
    1 context sentence
    Summary · context
    The metabolism and the urinary excretion of synthetic human and salmon calcitonin-(1--32) [hCT-(1--32), sCT-(1--32)] administered by constant infusions for 240 min were investigated in eight normal subjects.
  4. 04HumanNon-randomized trialPharmacokinetics

    In normal subjects, salmon calcitonin disappearance half-life did not differ significantly from human calcitonin half-life.

    In plain wordsIn normal subjects, salmon and human calcitonin did not differ significantly in disappearance half-life.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeDisappearance half-life
    Study

    n = 8

    Comparator
    Human calcitonin
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · constant infusion · 240 minAs given in this study (human).

    Source sentences

    Summary
    The half-lives of disappearance of hCT-(1--32) were faster compared to sCT-(1--32), but the difference was not statistically significant.
    1 context sentence
    Summary · context
    The metabolism and the urinary excretion of synthetic human and salmon calcitonin-(1--32) [hCT-(1--32), sCT-(1--32)] administered by constant infusions for 240 min were investigated in eight normal subjects.
  5. 05HumanNon-randomized trialPharmacokinetics

    In normal subjects, salmon calcitonin urinary clearance was about 0.1% of metabolic clearance during infusion.

    In plain wordsIn normal subjects, salmon calcitonin clearance through urine was about 0.1% of its metabolic clearance.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableUrinary clearance
    Study

    n = 8

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.04 mg · constant infusion · 240 minAs given in this study (human).

    Measurements

    Urinary clearance
    ≈ 0.1 % of MCR
    salmon calcitonin

    Source sentences

    Summary
    The urinary clearance of hCT-(1--32) determined during the 1 and 4 mg/240 min infusions of hCT-(1--32), as well as of sCT-(1--32) determined during the 0.04-mg infusions of sCT-(1--32) was about 0.1% of the MCR.
    1 context sentence
    Summary · context
    The metabolism and the urinary excretion of synthetic human and salmon calcitonin-(1--32) [hCT-(1--32), sCT-(1--32)] administered by constant infusions for 240 min were investigated in eight normal subjects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.